Sano Women's Health is pioneering antifungal innovation with its flagship product to treat recurrent vulvovaginal candidiasis (RVVC) using Occidiofungin - The Fungus Killer™. The first part of Phase 1 FDA human trials to treat recurrent vulvovaginal candidiasis (RVVC) has been successfully completed. Sano Women's Health is working to bring this innovative treatment to market, pending successful clinical trials and regulatory approval. RVVC is associated with chronic and recurrent yeast infections affecting up to 9 million women in the U.S. per year. FDA has granted Sano Women's Health qualified infectious disease product (QIDP) designation for its RVVC drug, which extends the expiration date on Occidiofungin patents for five years. Sano women's Health believes it's poised to address a multi-billion U.S. market for treating recurrent and drug-resistant vaginal yeast infections.
Sano Women's Health is a clinical stage company with a mission to develop novel therapeutic products for combatting infectious diseases that are specific to only women. Sano Women's Health is focused on making first-in-class antifungal therapeutics available to millions of women without an effective treatment. Therapeutics to treat vaginal yeast infections and nipple thrush are being developed using occidiofungin – the fungus killer©. Antimicrobial resistance (AMR) is a serious medical issue leaving a large patient population of women with no effective treatment options.
Sano Women's Health
Our Mission
At Sano Women's Health, we believe that innovation can foster higher standards of care and higher quality of life for women with fungal infections. We are developing first-in-class treatments for antimicrobial resistant fungi, and are exploring creative applications of our technologies to join the fight against RVVC and nipple thrush.
Our Story
Sano Chemicals Inc., DBA as Sano Women's Health, was founded in 2012 in Bryan, Texas near Texas A&M University, known globally for its innovative research program. We have worked closely with the University, and are independent recipients of awards through the Texas New Venture Competition and Mass Challenge, and have earned a reputation for integrity and ingenuity.
